Aimee DeGaetano Joins Vastrax as Global Head of Commercial and Clinical Affairs

Leading Clinical Research Organization Strengthens Expertise in Neurovascular Field


ANDOVER, Mass.–(BUSINESS WIRE)–Vastrax, a premier full-service Contract Research Organization (CRO) with a mission to expedite the development of cutting-edge technologies in the vascular market, proudly announces the appointment of Aimee DeGaetano as the Global Head of Commercial and Clinical Affairs.

“Our dedication to accelerating advancements in the vascular sector is unwavering, and Aimee’s appointment reinforces this commitment,” said Ryan Bouchard, President and CEO of Vastrax. “Aimee’s expertise aligns seamlessly with our mission, and we are thrilled to have her lead our Global Commercial Strategy and Clinical Affairs. Aimee’s appointment comes at a crucial juncture in Vastrax’s journey as we continue to lead the way in neurovascular clinical trials. Her expertise will significantly contribute to our efforts in helping our clients advance ground-breaking technological solutions that have the potential to transform the lives of patients worldwide.”

Aimee is a registered dietician (RD) and holds a master’s in public health (clinical epidemiology). She is currently completing a doctorate in health science at Eastern Virginia Medical School. She has held various leadership roles in medical technology companies, focusing on clinical trials, medical affairs, and key opinion leader engagement. Her unique blend of skills perfectly aligns with Vastrax’s multifaceted approach to driving efficient technology approvals.

“I am honored to contribute to Vastrax’s pivotal role in assisting our clients to expedite the introduction of groundbreaking vascular technologies,” commented Aimee DeGaetano. “Together, we will fortify our commitment to clinical trials, integrating novel innovations, strategies and technologies to enhance patient care and improve outcomes.”

About Vastrax, Inc.

Vastrax is a cutting-edge full-service Contract Research Organization specializing in expediting the development of cutting-edge technologies in the vascular market. With an expert team possessing over 100 years of combined clinical, commercial, and regulatory experience, Vastrax is at the forefront of pioneering innovations, delivering transformative products to market efficiently. For more information please visit us at www.vastrax.com and follow us on LinkedIn.

Contacts

Tara DiMilia

908-369-7168

Tara.DiMilia@tmstrat.com

Staff

Recent Posts

TempraMed Launches National Brick and Mortar Pharmacy Roll Out, Shipping Products to Maccabi Pharmacies Across Israel

Key Commercialization Milestone in Retail Pharmacy Network that Serves Over 2.8 Million Insured MembersVancouver, British…

4 hours ago

NuGen Medical Devices Inc. Provides Update on Health Canada License

Toronto, Ontario--(Newsfile Corp. - February 5, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"…

13 hours ago

Field Medical Presents Late Breaking Field PULSE Trial Data at AF Symposium 2026

Demonstrating Instantaneous Ablation Through High-Voltage Waveforms and Efficient Point-by-Point Pulsed Field AblationCARDIFF-BY-THE-SEA, Calif., Feb. 5,…

13 hours ago

LEADOPTIK Announces First-in-Human Use of FDA-Cleared LIA™ System

SAN JOSE, Calif., Feb. 5, 2026 /PRNewswire/ -- LEADOPTIK, Inc., a medical technology company focused…

13 hours ago

Dräger PSS® AirBoss SCBA Now Available for Purchase in North America

Now Available for Purchase, AirBoss Delivers an NFPA 1970:2025 SCBA Built for the Way American…

19 hours ago

Greenway Health® Named Most Improved Physician Practice Solution 2026 by KLAS Research

KLAS recognition highlights Greenway's momentum in modernizing physician practice technologyTAMPA, Fla., Feb. 5, 2026 /PRNewswire/…

19 hours ago